𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lymphoscintigraphy in patients with malignant melanoma: A quantitative and qualitative evaluation of its usefulness

✍ Scribed by Lennart Bergqvist; Sven-Erik Strand; Larsolof Hafström; Per-Ebbe Jönsson

Publisher
Springer
Year
1984
Tongue
English
Weight
621 KB
Volume
9
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of transsphenoidal hypophysec
Evaluation of transsphenoidal hypophysectomy in the management of patients with advanced malignant melanoma
✍ David H. Lawson; Daniel W. Nixon; Marcus L. Black; George T. Tindall; David A. B 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB 👁 2 views

Transsphenoidal hypophysectomy was performed in 13 patients with advanced malignant melanoma. Although three minor responses were observed, there were no complete or partial responses. All three patients with bone pain had a decrease in discomfort lasting 1-2 months. All five patients with minor res

A quantitative and qualitative study of
A quantitative and qualitative study of blood monocytes in patients with bronchogenic carcinoma
✍ Henrik Nielsen; Jørgen Bennedsen; Severin Olesen Larsen; Per Dombernowsky; Kaj V 📂 Article 📅 1982 🏛 Springer-Verlag 🌐 English ⚖ 572 KB

Absolute circulating number and functions of blood monocytes (i.e., pinocytosis, phagocytosis, and chemotaxis) were studied in 25 patients with untreated bronchogenic carcinoma and in 28 control subjects. The absolute circulating monocyte count was increased in 20 (80%) of the patients. There was no

Evaluation of interferon alpha-2B and th
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026
✍ Laura F. Hutchins; James Moon; Joseph I. Clark; John A. Thompson; Marianne K. La 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND. Southwest Oncology Group protocol 0026 evaluated interferon alpha‐2b plus thalidomide in patients with disseminated melanoma. Endpoints were 6‐month progression‐free survival rate, response rate, and toxicity. ## METHODS. Twenty‐six patients with Stage IV melanoma, mea

Phase II evaluation of dibromodulcitol a
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma
✍ David A. Amato; Howard Bruckner; DuPont Guerry; Arlene Ash; Geoffrey Falkson; Er 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 418 KB

In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant